UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas

ONCOLOGY

Volumn 11, Issue 9 SUPPL. 10, 1997, Pages 124-127

  Mani, Sridhar ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; UFT;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; HEPATOBILIARY SYSTEM TUMOR; HUMAN; MULTICENTER STUDY; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE;

ADENOCARCINOMA; ADULT; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHOLANGIOCARCINOMA; DRUG COMBINATIONS; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; QUALITY OF LIFE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0030834050     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (2)

1. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1988.
2. Ohashi O, Yamamoto M, Ishida H, et al: Retrospective analysis of postoperative chemotherapy with UFT against pancreatic cancer. Can To Kagaku Ryoho 22:933-993, 1995.